Supernus Pharmaceuticals, Inc. SUPN
Set alert
At close · Oct 30
After hours · Oct 30, 4:05 PM ET
- YTD
- -15.65%
- 1 year
- -25.81%
- Open
- 42.07
- Prev close
- 41.84
- Mkt cap
- 2.44B
- Vol
- 2.82M
- Avg vol
- 885.96K
- EPS
- -1.92
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 39.53
- High
- 43.72
- Forward P/E
- 9.79
- Beta
- 0.55
- Short ratio
- 5.36
- Inst. own
- 105.93%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 42.61
- 200-d avg
- 47.34
- 1y target
- 60.50
5D chart
Events in this range
- Oct 29, 2026Earnings: 0.35; estimate 0.49; surprise -28.57%
Signals (163)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:20 AM | 2 days ago |
| RSI: Overbought | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:50 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:50 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:20 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:10 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:15 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:40 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:15 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
3 days ago seekingalpha.com
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript
3 days ago zacks.com
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.01 per share a year ago.
3 days ago marketbeat.com
Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals NASDAQ: SUPN reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is…
3 days ago benzinga.com
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
3 days ago benzinga.com
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
-
3 days ago benzinga.com
Supernus Pharmaceuticals Raises FY2026 Sales Guidance from $860.000M-$890.000M to $875.000M-$900.000M vs $877.738M Est
Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2026 sales outlook from $860.000 million-$890.000 million to $875.000 million-$900.000 million vs $877.738 million estimate.
-
3 days ago benzinga.com
Supernus Pharmaceuticals Q3 EPS $0.35 Beats $0.02 Estimate, Sales $226.771M Beat $215.917M Estimate
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.02 by 1650 percent. This is a 143.75 percent increase over losses…
3 days ago globenewswire.com
Supernus Announces Third Quarter 2026 Financial Results
ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of…
4 days ago prnewswire.com
Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600
NEW YORK, Oct. 28, 2026 /PRNewswire/ -- Huron Consulting Group Inc. (NASD: HURN) will replace Supernus Pharmaceuticals Inc. (NASD: SUPN) in the S&P SmallCap 600 before the opening of trading on…
1 week ago gurufocus.com
Is Supernus Pharmaceuticals Inc (SUPN) a Bargain After 3.3% Drop? GF Value Says Undervalued
On October 23, 2026, Supernus Pharmaceuticals Inc (SUPN) shares fell 3.3% to $40.70, moving within a 52-week range of $37.54 to $59.68. The stock's performance
-
1 week ago benzinga.com
MSG Rangers To Replace Arbor Realty Trust In The S&P SmallCap 600 Effective On October 27; Huron Consulting Group To Replace Supernus Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Monday, November 2
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20261022-1485639/1485639_msgs-supn-6.pdf
1 week ago zacks.com
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
1 week ago benzinga.com
Reported Earlier, Supernus Secures Seven Years Of FDA Orphan-Drug Exclusivity For ONAPGO, Seeks Second Supplier Approval By Mid-2027
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGOAdditionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by…
1 week ago globenewswire.com
Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by…
1 week ago globenewswire.com
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of…
2 weeks ago seekingalpha.com
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
Supernus Pharmaceuticals merges with Indivior, gaining operational control and exposure to a larger, cash-generating CNS and addiction platform. SUPN's growth products now comprise 80% of revenue,…
2 weeks ago defenseworld.net
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Rated “Hold” by Sell-Side Brokerages
Shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) have received an average rating of "Hold" from the six brokerages that are presently covering the company, Marketbeat.com…
3 weeks ago defenseworld.net
Head-To-Head Contrast: Supernus Pharmaceuticals (NASDAQ:SUPN) and Shineco (NASDAQ:SISI)
Shineco (NASDAQ: SISI - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two…
1 month ago defenseworld.net
Head-To-Head Contrast: Harrow (NASDAQ:HROW) & Supernus Pharmaceuticals (NASDAQ:SUPN)
Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
1 month ago businesswire.com
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
1 month ago businesswire.com
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
2 months ago globenewswire.com
Supernus Pharmaceuticals to Participate in September Investor Conferences
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of…
2 months ago globenewswire.com
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with…
2 months ago gurufocus.com
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for
2 months ago businesswire.com
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401…
2 months ago benzinga.com
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.…
2 months ago benzinga.com
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold…
3 months ago benzinga.com
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.
-
3 months ago benzinga.com
UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.42 by 26.19 percent. This is a 32.5 percent increase over…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…
-
3 months ago benzinga.com
Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that they have entered into a definitive agreement to combine in a tax-free all-stock…
-
3 months ago benzinga.com
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67
Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $63 to $67.
6 months ago benzinga.com
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript
Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript
-
6 months ago benzinga.com
Supernus Pharmaceuticals Affirms FY2026 Sales Guidance of $840.000M-$870.000M vs $862.242M Est
Supernus Pharmaceuticals (NASDAQ:SUPN) affirms FY2026 sales outlook from $840.000 million-$870.000 million to $840.000 million-$870.000 million vs $862.242 million estimate.
-
6 months ago benzinga.com
Supernus Pharmaceuticals Q1 EPS $(0.04) Misses $(0.01) Estimate, Sales $207.705M Beat $192.918M Estimate
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 300 percent. This is a 80.95 percent increase over…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
8 months ago benzinga.com
Earnings Scheduled For February 24, 2026
Earnings Scheduled For February 24, 2026
-
12 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 months ago benzinga.com
Earnings Scheduled For November 4, 2025
Earnings Scheduled For November 4, 2025
-
12 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session
-
1 year ago benzinga.com
Earnings Scheduled For February 25, 2025
Earnings Scheduled For February 25, 2025
1 year ago benzinga.com
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
1 year ago benzinga.com
Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
1 year ago benzinga.com
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 647 companies set new 52-week lows.